We observed a wide range of RSs among elderly ESBC patients in the NCDB. Further research is needed to determine if gene expression assays are capable of risk-stratifying within this population, as a means for directing adjuvant RT recommendations after BCS. Should this be proven, our findings would suggest that ODX-directed decision-making is theoretically cost-effective at a conservative willingness-to-pay threshold of $50,000/QALY.
Charles E. Rutter, MD, Nataniel H. Lester-Coll, MD, Suzanne B. Evans, MD, MPH; Department of Therapeutic Radiology, Yale University School of Medicine
OBJECTIVE: Adjuvant breast radiotherapy (RT) after breast-conserving surgery (BCS) in elderly women with early-stage breast cancer (ESBC) confers a local control benefit but no improvement in overall survival. Hence, the role of RT in this population is uncertain. In the separate context of adjuvant chemotherapy recommendations for node-negative ESBC, gene expression testing has allowed risk-adapted decision making and has had a marked impact on clinical practice. We sought to determine the potential role and cost-effectiveness of gene expression testing in directing adjuvant RT decisions for elderly ESBC patients, given a published relationship of Oncotype DX (ODX) results with local-regional recurrence risk.
METHODS: The distribution of ODX recurrence scores (RSs) among elderly women (aged ≥ 70 yr) with estrogen receptor–positive ESBC (pT1N0M0) post-BCS was defined within the National Cancer Data Base (NCDB), using standard definitions of low (< 18), intermediate (18–30), and high risk (> 30). Next, a decision tree was constructed to determine the overall cost-effectiveness of ODX in directing RT recommendations. Local-regional recurrence estimates at 10 years were extrapolated from the literature and assumed to be 1%, 3%, and 5% in patients with low, intermediate, and high RSs, respectively, following BCS, RT, and 5 years of tamoxifen. Rates of adjuvant radiotherapy utilization for each RS stratum were based upon published patterns of RS-guided adjuvant chemotherapy utilization.
RESULTS: We identified 2,564 elderly ESBC patients treated between 2007 and 2011 within the NCDB with ODX RS results. Median age and tumor size were 73 years (range: 70–90 yr) and 1.2 cm (range: 0.1–2 cm), respectively. Median RS was 15 (standard deviation [SD] = 8.3). RS was low, intermediate, and high in 69.2%, 28.3%, and 2.5% of patients, respectively. Neither age nor tumor size was associated with RS. ODX-directed adjuvant radiotherapy recommendations resulted in a net savings of $1,163.05 per patient and a utility decrease of 0.024 quality-adjusted life years (QALYs) relative to current clinical practice, yielding an incremental cost-effectiveness ratio for ODX-directed adjuvant radiotherapy of $47,920.78/QALY.
CONCLUSIONS: We observed a wide range of RSs among elderly ESBC patients in the NCDB. Further research is needed to determine if gene expression assays are capable of risk-stratifying within this population, as a means for directing adjuvant RT recommendations after BCS. Should this be proven, our findings would suggest that ODX-directed decision-making is theoretically cost-effective at a conservative willingness-to-pay threshold of $50,000/QALY.
Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.